Company intelligence / Profile preview

Prolocor

King of Prussia, Pennsylvania, United Statesprolocor.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

Prolocor has developed and clinically validated a precision diagnostic test that quantifies platelet FcγRIIa, enabling improved risk prediction for subsequent cardiovascular events in patients with atherosclerotic cardiovascular disease. Clinical trials have demonstrated high accuracy and reliability, with strong intra/inter-test consistency. The technology is now commercialized following regulatory approvals, with ongoing efforts to expand its clinical utility and market reach.

Therapeutic areas: Cardiovascular
Modalities: Diagnostic test (precision diagnostic)Software (for analysis)
Industry: Protein Biomarker Diagnostics

Partnerships

Slingshot Biosciences (collaboration for TruCytes™ cell mimics used in analytic validation of the assay)

Beyond the preview

Go deeper on Prolocor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prolocor.

Explore the full profile